Highly Potent SARS-CoV-2 Neutralization by Intravenous Immunoglobulins manufactured from Post-COVID-19 and COVID-19-Vaccinated Plasma Donations.
COVID-19
CoVIg-19
Primary immunodeficiency
SARS coronavirus 2 antibody potency
SARS-CoV-2
Secondary immunodeficiency
hyperimmune globulin
immunoglobulin
intravenous immune globulin
neutralizing antibodies
plasma
prophylaxis
Journal
The Journal of infectious diseases
ISSN: 1537-6613
Titre abrégé: J Infect Dis
Pays: United States
ID NLM: 0413675
Informations de publication
Date de publication:
22 11 2021
22 11 2021
Historique:
received:
25
08
2021
accepted:
17
09
2021
pubmed:
21
9
2021
medline:
1
10
2022
entrez:
20
9
2021
Statut:
ppublish
Résumé
From September 2020, some immunoglobulin lots from US plasma contained neutralizing antibodies against the newly emerged severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Paralleled by the increasing numbers of post-coronavirus disease 2019 (COVID-19) donors, immunoglobulin lot antibody positivity increased to 93% by January 2021, at a mean titer of approximately 30 IU/mL. The correlation predicted that anti-SARS-CoV-2 potency would reach 345 IU/mL by July 2021. In addition to post-COVID-19 donors, the rapidly increasing number of plasma donors vaccinated against COVID-19 resulted in a mean antibody titer of >600 IU/mL in July 2021 immunoglobulin lots, with SARS-CoV-2 antibody titers for several lots even higher than those of earlier produced hyperimmune globulin products.
Identifiants
pubmed: 34543421
pii: 6372887
doi: 10.1093/infdis/jiab482
pmc: PMC8499975
doi:
Substances chimiques
Antibodies, Neutralizing
0
Antibodies, Viral
0
Immunoglobulins, Intravenous
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1707-1711Informations de copyright
© The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America.